Are Johnson & Johnson (NYSE:JNJ)’s Fundamentals Enough to Outperform

Johnson & Johnson (NYSE:JNJ) has a beta of 0.72, a 12-month trailing P/E ratio of 30.26, and a growth ratio of 5.40. The stock’s Relative Strength Index (RSI) is 55.38, with weekly volatility at 1.02% and ATR at 2.43. The JNJ stock’s 52-week price range has touched low of $133.65 and a $173.65 high. Its shares traded lower over the last trading session, losing -0.02% on 04/06/21. The shares fell to a low of $163.00 before closing at $163.39. Intraday shares traded counted 5.06 million, which was 38.37% higher than its 30-day average trading volume of 8.21M. JNJ’s previous close was $163.43 while the outstanding shares total 2.63B.

Investors have identified the Drug Manufacturers – General company Johnson & Johnson as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $434.17 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Johnson & Johnson (JNJ) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 51.24 billion total, with 42.49 billion as their total liabilities.

Having a look at the company’s valuation, the company is expected to record 10.22 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on JNJ sounds very interesting.

Is the stock of JNJ attractive?

In related news, EVP, Global Corp Aff & COO, Sneed Michael E sold 54,662 shares of the company’s stock in a transaction that recorded on Dec 09. The sale was performed at an average price of 152.93, for a total value of 8,359,460. As the sale deal closes, the EVP, Chief GSC Officer, Wengel Kathryn E now sold 16,115 shares of the company’s stock, valued at 2,473,938. Also, EVP, WW Chair, Medical Devices, McEvoy Ashley sold 29,000 shares of the company’s stock in a deal that was recorded on Jul 28. The shares were price at an average price of 147.47 per share, with a total market value of 4,276,630. Following this completion of acquisition, the 10% Owner, JOHNSON & JOHNSON now holds 725,000 shares of the company’s stock, valued at 12,325,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.

10 out of 18 analysts covering the stock have rated it a Buy, while 6 have maintained a Hold recommendation on Johnson & Johnson. 0 analysts has assigned a Sell rating on the JNJ stock. The 12-month mean consensus price target for the company’s shares has been set at $185.44.

LEAVE A REPLY

Please enter your comment!
Please enter your name here